FDA Approval for Paxil for Hot Flashes A Cruel Joke ?

Demonstration of Hysteria by Charcot

SSRI Antidepressants for Menopausal Hot Flashes ? 

Surely, You Must Be Joking.

This article is part two of a series. For part one, click here.

Instead of using hormone replacement as a treatment for menopausal hot flashes, mainstream medicine docs will sometimes prescribe SSRI antidepressants off-label.(22-26)  Off-label use means that the SSRI drug has not been FDA approved for treatment of menopausal symptoms of hot flashes.

SSRI Antidepressant Drug Off-Label Use for Hot Flashes (24)

Chemical name     Trade Name
fluoxetine                 Prozac
paroxetine               Paxil
venlafaxine              Effexor
escitalopram           Lexapro

For the fist time in its history the FDA recently approved an SSRI antidepressant, Brisdelle, also named Paxil (paroxetine), for the treatment of menopausal hot flashes.(1)

The clinical trial which generated the data for FDA approval was funded by Noven Pharmaceuticals.  The lead author of  the study was James A Simon, an MD who disclosed financial relationships with Noven and thirty other pharmaceutical companies.  (2-4)

FDA Advisory Committee Votes Against FDA Approval

The FDA approved the paroxetine drug against the vote of an FDA advisory committee.  They voted 10-4 against approval in a meeting held March 2013. (5-17)  Click here for a transcript of the FDA meeting.:  Transcript_FDA_Advisory _MArch_2013.

Dr. Mary Carol Jennings made a statement against approval to the FDA Advisory Committee because the drug carries adverse effects which outweigh any potential benefit.

No Meaningful Reduction in Hot Flashes Compared to Placebo

Women in Dr. Simon’s Brisdelle (paroxetine) clinical trial started with about 10 hot flashes per day. After 12 weeks, those on paroxetine had  4 hot flashes per day compared to 5-6 for the placebo group.  Members of the FDA advisory committee said such a marginal difference between the drug and placebo would not be meaningful to women.(New York Times)(13)  That is why they voted against approval.  It is not difficult to understand why SSRI antidepressants are medically ineffective for menopausal symptoms.  Menopause is a hormone deficiency state. Paroxetine (Paxil) is  not a hormone and can never replace one. (Hormones Matter)

Abuse and Mistreatment of Women

In my opinion, the use of psycho-active drugs such as SSRI anti-depressants for treatment of symptoms caused by menopausal  hormone deficiency is an abuse and mistreatment of women bordering on criminal behavior by the medical system.  This is a medical practice that should be halted immediately.

History will no doubt regard this practice as yet another example of medical iatrogenesis in women, to be eventually thrown into the garbage heap with all the other discredited treatments and procedures in the history of medicine..

Adverse Effects of SSRI

Of all the SSRI drugs, Paroxetine (Paxil) is one of the most addictive and habit forming.  The FDA has warned that withdrawal from paroxetine can be severe. (BMJ).  The drug has numerous adverse side effects including increased suicidal activity , loss of libido and sexual dysfunction.

The History of Medical Iatrogenesis in Women

Demonstration of Hysteria by Charcot

Left Image: Demonstration of Hysteria by Charcot .  Courtesy of Department of Neurology, The University of Illinois at Chicago

Over-Diagnosis of “Hysteria” in Women.

Perhaps one of the early examples of medical iatrogenesis in  women occurred in the 1800’s in Paris with the over-diagnosis of “Hysteria” by Dr Charcot (34)  Dr. Martin Charcot of the Paris hospital La Salpetriere diagnosed, on the average, 10 hysterical women each day,  The number of women diagnosed and hospitalized for “hysteria” increased from  from one percent in 1841 to 17 percent in 1883.(34)

DES  Diethyl-Stilbestrol

A more recent historical example of medical iatrogenesis in women is the story of DES (Diethylstilbestrol) the first synthetic hormone replacement drug. invented in 1938.  This carcinogenic monster hormone was approved by the FDA and given to millions of women from 1940 until it was banned in 1975 when it was shown carcinogenic.  The first report of cervical cancer in the daughters of DES treated women was published in April 1971 in the New England Journal of Medicine.(42-43)


Our next example of medical iatrogenesis in women is Premarin, a horse estrogen isolated from the urine of pregnant horses.   Available since FDA approval in 1942, Premarin has caused an estimated 15,000 cases of endometrial cancer, representing the largest epidemic of serious iatrogenic disease ever reported.(44-47)    One might think this would be the end of any drug.   However Premarin was promptly rehabilitated with the addition of another synthetic hormone, a progestin, to prevent endometrial cancer.  Thus, in 1995, Prempro was born, a synthetic hormone pill containing both Premarin (the horse estrogen) and Provera (the progestin).  Again, this was FDA approved,  thought safe and handed out freely to millions of women.


Our next example of medical iatrogeniesis in women is Prempro , the combination of Premarin with Provera (medroxyprogersterone) found to cause breast cancer and heart disease.  Four large scale studies showed increased breast cancer and heart disease from this estrogen-progestin combination pill.  The  Breast Cancer Detection Demonstration Project, published in 2000, showed an eight fold increase in breast cancer for estrogen-progestin users.(48)  The Swedish Record Review, published in 1996, had a fourfold increase in breast cancer with progestin use.(49)  The Million Woman study, published in Lancet in 2003, had a fourfold increase in breast cancer for estrogen-progestin combination users compared to estrogen alone users.(50)  Finally in 2002, JAMA published the Women’s Health Initiative (WHI), an NIH funded study terminated early because of increased breast cancer and heart disease in the estrogen-progestin users.(51)  Incredibly, the medical system is still dispensing this discredited drug to women.

SSRI Antidepressants Shown to be No More Effective Than Placebo

The next example medial iatrogeneiss in women is SSRI antidepressant drugs that were shown to have little benefit for patients with mild to moderate depression.  The benefits of SSRI drugs are equivalent to placebo pills.(52).  In spite of these studies. discredited SSRI drugs are still being dispensed freely to millions of women.

Mistreatment of Women by the Medical System – Excessive Hysterectomies 

The National Women’s Health Network has written extensively on the overuse of hysterectomies.  Ernst Bartsich, M.D., a  surgeon at Cornell in New York. says ” Of the 617,000 hysterectomies performed annually, “from 76 to 85 percent” may be unnecessary. “(CNN)  Thus representing another example of mistreatment of women by the medical system.

More Discredited Treatments Used on Women:

Radical Mastectomy   A disfiguring operation which provided no benefit compared to lesser procedures such as lumpectomy.

Bone Marrow Transplantation for Breast Cancer
Which was abandoned when studies showed it offered no benefit.(J Clin Oncology)

Kyphoplasty for Osteoporotic Fracture  Was discredited when studies found no benefit compared to a sham procedure

Arthroscopy for Osteoarthritis   Was abandoned after studies found no benefit compared to conservative treatment.

Screening mammograms   For under 50 age women offers more harm than benefit.

Hot Flashes Are Caused By Hormone Deficiency of Menopause

Menopausal symptoms are not caused by a SSRI antidepressant deficiency.  They are caused by hormone deficiency.  SSRI drugs are addictive psychiatric drugs that do not address the hormone deficiency of menopause.  To suggest them as a treatment for hormone deficiency is ludicrous, and creates a new population of women as medical victims.

Safe and Effective Treatment : BioIdentical Hormones

The safest and most effective treatment for menopausal symptoms of hot flashes is a biodentical hormone program.  Progestins and other synthetic hormones are associated with increased risk of cancer and heart disease.  On the other hand, Bioidentical Hormones are safe, effective and are not associated with increased risk of cancer or heart disease. That is why bioidentical hormones are the preferred treatment.  Read the safety and importance of bioidentical hormones.

Don’t Be a Victim of SSRI Antidepressants for Menopausal Hot Flashes

Don’t be a medical victim. Avoid the SSRI for menopause trap.

This article is part two of a series. For part one, click here.

Articles with related interest

Bioidentical Hormones Beneficial After Hysterectomy

Lexepro for Hot Flashes , a Joke?

The Safety of Bio-Identical Hormones

The Importance of BioIdentical Hormones

Bioidentical Hormones Prevent Arthritis

Bioidentical Hormone Estrogen Prevents Heart Disease

Morning Rounds With Steven Economou MD

Don’t Monkey With My Hormones

Waking Up from the Synthetic Hormone Nightmare

HRT Does Not Cause Breast Cancer

author : Jeffrey Dach MD

1) http://www.prnewswire.com/news-releases/noven-announces-positive-phase-3-data-results-for-investigational-low-dose-nonhormonal-therapy-for-the-treatment-of-vasomotor-symptoms-associated-with-menopause-172403951.html
Data from 12- and 24-Week Pivotal Studies Selected to Be Presented at The North American Menopause Society Annual Meeting

MIAMI, FL, NEW YORK, NY and ORLANDO, FL, Oct. 3, 2012 /PRNewswire/ — Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced positive results from two multicenter, double-blind, randomized, placebo-controlled Phase 3 clinical studies evaluating low-dose mesylate salt of paroxetine (LDMP; 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. Menopausal VMS, which comprise hot flashes and night sweats, affect up to 80 percent of women experiencing menopause, and many women report them as the most bothersome symptoms related to the condition. The co-primary endpoints of the studies evaluated weekly reductions in the frequency and severity of VMS associated with menopause in patients taking LDMP versus placebo at Week 4 and Week 12. The 24-week study achieved statistical significance in all co-primary endpoints. The 12-week study also achieved statistical significance for all co-primary endpoints, except for severity of VMS symptoms at Week 12.  “If a patient is unable or unwilling to take hormone therapy, which is currently the only FDA-approved treatment option for menopausal hot flashes and night sweats, these symptoms often go untreated,” said James A. Simon, MD, CCD, NCMP, FACOG, clinical professor of obstetrics and gynecology at the George Washington University School of Medicine, Washington, D.C. and study investigator. “The approval of a nonhormonal therapy would be an important milestone to expand available options for women seeking treatment for VMS associated with menopause.”

2) http://www.endocrinetoday.com/pda.aspx?rid=101294
Low-dose mesylate salt of paroxetine effective in treating vasomotor symptoms
Posted on October 12, 2012 n/a  Simon JA. S-2. Presented at: the North American Menopause Society 23rd Annual Meeting; Oct. 3-6, 2012; Orlando, Fla.

Disclosure: Simon is on the advisory board/review panel, has received grant or research support from, and/or has been on the speakers’ bureau for various entities, including:
Abbott Laboratories, Agile Therapeutics, Amgen, Ascend Therapeutics, Azur Pharma, Bayer, BioSante Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals,
Depomed, Endoceutics, Fabre-Kramer Pharmaceuticals, Laboratoire HRA Pharma, Meditrina Pharmaceuticals, Merck, Merrion Pharmaceuticals,
NDA Partners LLC, Novartis Pharmaceuticals Corp., Novo Nordisk, Novogyne, Palatin Technologies, Pfizer, Shionogi, Slate Pharmaceuticals,
Sprout Pharmaceuticals, Teva Women’s Health, Trovis Pharmaceuticals LLC, Warner Chilcott and Watson Pharmaceuticals.

3) http://www.medscape.org/viewarticle/585659
James A Simon, MD, CCD, FACOG
Clinical Professor, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, George Washington University, Washington, DC; Medical Director, Women’s Health & Research Consultants, Washington, DC; President, James A. Simon, MD, PC, Washington, DC
Disclosure: James A. Simon, MD, CCD, FACOG, has disclosed that he has served as a consultant or on the advisory boards of Allergan, Alliance for Better Bone Health, Ascend, Barr, Bayer, BioSante, Concert Pharmaceuticals, Corcept Therapeutics, Inc., Depomed, Inc., GlaxoSmithKline, KV, Meditrina, Merck, Merrion, Nanma/Tripharma/Trinity, Novo Nordisk, Novogyne, Pear Tree, QuatRx, Roche, Sciele, Solvay, Ther-Rx, Warner Chilcott, and Wyeth. Dr. Simon has also disclosed that he has received grant/research support from BioSante, Boehringer Ingelheim, FemmePharma, GlaxoSmithKline, Nanma/Tripharma/Trinity, Novartis, and Procter & Gamble.

Dr. Simon has also disclosed that he has served on the speaker’s bureau for Ascend, Barr, Bayer, GlaxoSmithKline, KV, Merck, Novartis, Novogyne, Sciele, Ther-Rx, Warner Chilcott, and Wyeth.

4) http://www.medscape.org/viewarticle/705130
James A. Simon, MD, CCD, FACOG
Clinical Professor, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, George Washington University, Washington, DC; Medical Director, Women’s Health & Research Consultants, Washington, DC; President, James A. Simon, MD, PC, Washington, DC

Disclosure: James A. Simon, MD, CCD, FACOG, has disclosed that he has served as a consultant and/or on the advisory boards of Allergan, Inc.; Alliance for Better Bone Health; Ascend; Barr Laboratories, Inc.; Bayer HealthCare Pharmaceuticals; BioSante Pharmaceuticals, Inc.; Concert Pharmaceuticals, Inc.; Corcept Therapeutics Inc.; Depomed, Inc.; GlaxoSmithKline; KV Pharmaceutical Company; Meditrina Pharmaceuticals, Inc.; Merck & Co., Inc.; Merrion Pharmaceuticals, Ltd.; Nanma/Tripharma/Trinity; Novo Nordisk; Novogyne Pharmaceuticals; Pear Tree Pharmaceuticals, Inc.; QuatRx Pharmaceuticals Company; Roche Laboratories Inc.; Sciele Pharma, Inc.; Solvay Pharmaceuticals, Inc.; Ther-Rx Corporation; Warner Chilcott; and Wyeth Pharmaceuticals Inc. Dr. Simon has also disclosed that he has received grants and/or research support from BioSante Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; FemmePharma Global Healthcare, Inc.; GlaxoSmithKline; Nanma/Tripharma/Trinity; Novartis Pharmaceuticals Corporation; and Procter & Gamble.
Dr. Simon has also disclosed that he has served on the speaker’s bureau of Ascend; Barr Laboratories, Inc.; Bayer HealthCare Pharmaceuticals; GlaxoSmithKline; KV Pharmaceutical Company; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novogyne Pharmaceuticals; Sciele Pharma, Inc.; Ther-Rx Corporation; Warner Chilcott; and Wyeth Pharmaceuticals Inc.
5) http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm359030.htm
FDA NEWS RELEASE June 28, 2013
FDA approves the first non-hormonal treatment for hot flashes associated with menopause. The U.S. Food and Drug Administration today approved Brisdelle (paroxetine)to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Brisdelle, which contains the selective serotonin reuptake inhibitor paroxetine mesylate, is currently the only non-hormonal treatment for hot flashes approved by the FDA.
There are a variety of FDA-approved treatments for hot flashes, but all contain either estrogen alone or estrogen plus a progestin.
6) http://abclocal.go.com/kabc/story?section=news/health/your_health&id=9159024
Denise Dador LOS ANGELES (KABC) — The Food and Drug Administration just approved the first non-hormonal drug to treat hot flashes. “Noven Therapeutics Brisdelle is actually the same ingredient that’s in the FDA-approved medication Paxil, which is an antidepressant,” said gynecologist Dr. Steven Rabin.
7) http://www.huffingtonpost.com/2013/07/01/menopause-treatment-fda-approves-first-nonhor_n_3528602.html
FDA Approves First Non-Hormonal Treatment For Menopausal Hot Flashes Reuters  07/01/2013
8) Noven wins FDA approval for first non-hormonal drug to treat menopausal symptoms  The U.S. Food and Drug Administration has approved a new, non-hormonal medication for treating hot flashes and night sweats in women that was developed by Miami-based Noven Pharmaceuticals.
The medication, called Brisdelle, is the first non-hormonal treatment option for hot flashes and night sweats associated with menopause, the company said
.9) http://www.nydailynews.com/life-style/health/nonhormonal-hot-flash-treatment-approved-fda-article-1.1388094#ixzz2YwIqbVvJ
First nonhormonal treatment for hot flashes, Brisdelle, approved by FDA
The drug, which contains the antidepressant peroxetine, has been prescribed off-label by doctors for years as a treatment for menopausal symptoms. Many women prefer not to take hormonal therapy because some scientific evidence shows an association with increased cancer risk.  By Tracy Miller / NEW YORK DAILY NEWS
10) http://www.ibtimes.com/fda-approves-first-nonhormonal-hot-flash-treatment-despite-advisory-panel-recommendation-1328369
FDA Approves First Nonhormonal Hot Flash Treatment, Despite Advisory Panel Recommendation  By Roxanne Palmeron June 28 2013 4:55 PM
11) http://www.healthline.com/health-blogs/hold-that-pause/antidepressant-brisdelle-approved-by-fda-hot-flashes-women
Antidepressant Brisdelle Approved by FDA for Hot Flashes in Women By Magnolia Miller | Published Jul 2, 2013

12) http://www.medscape.com/viewarticle/807082
Brisdelle Okayed as First Nonhormonal Rx for Hot Flashes  Robert LowesJun 28, 2013

13) http://www.nytimes.com/2013/06/29/business/fda-approves-a-drug-for-hot-flashes.html?_r=0
F.D.A. Approves a Drug for Hot Flashes By ANDREW POLLACK June 28, 2013

14) http://www.dranitapetruzzelli.com/
New Menopause Drug Comes with Side Effects
The FDA has approved a new drug to treat hot flashes in menopausal women called Brisdelle. It is a form of Paxil, an antidepressant.

Antidepressants are not a new treatment for menopausal symptoms.  Medications such as Effexor, Paxil, and Prozac can decrease hot flashes and night sweats. They are not as effective as hormone therapy and side effects can include nausea, dizziness, weight gain, and sexual dysfunction. They can also be difficult to stop.

Neurontin, a seizure medication and Clonidine, a blood pressure medication can also help menopausal symptoms such as hot flashes and night sweats. These two can also cause side effects similar to those of antidepressants.

However, these medications may be a safe option for someone who is not a candidate for hormone therapy, such as breast cancer patients.

FDA’s advisory panel voted against approval of Brisdelle for treatment of hot flashes and for the very reason you described.

leave reply here :

15) http://www.hormonesmatter.com/advisory-panel-votes-no-but-fda-approves-antidepressant-for-hot-flashes-anyway/
Advisory Panel Votes No, But FDA Approves Antidepressant for Hot Flashes Anyway
Tuesday, July 2nd, 2013 / Robin Karr

Brisdelle Background

Noven Pharmaceuticals makes Brisdelle and funded the studies on the use of Brisdelle to treat hot flashes.

Dr. James A. Simon, Clinical Professor of Obstetrics and Gynecology at the George Washington University School of Medicine in Washington DC,
led the study. Dr. Simon openly reports having a financial relationship with Noven. The fact that Noven supported the study and provided the drug for the study, along with the fact that the lead doctor overseeing the study has financial ties with Noven, is troubling in my opinion, but standard fair in pharmaceutical research.

16) http://www.cjr.org/the_second_opinion/brisdelle_novens_new_hot_flash_drug_is_not_so_new.php
Flash: this new drug is not so new Disappointing coverage of Brisdelle, the hot flash drug, misses a chance to expose one of Big Pharma’s oldest tricks
By Sibyl Shalo Wilmont

17) http://online.wsj.com/article/SB10001424127887324328204578573933118005340.html
FDA Approves Drug for Hot Flashes
Non-Hormonal Medication Aimed at Treating Main Symptom of Menopause

18) http://www.peoplespharmacy.com/2013/07/01/new-fda-drug-approval-blessing-or-boondoggle/
New FDA Drug Approval: Blessing or Boondoggle? July 1, 2013 in Drug Library, People’s Pharmacy Alerts

19) Low  dose paxil now for hot flashes  Started by Karma , Jun 30 2013 03:27 PM
Saw this on the news tonight and looked up an article on it.  On Friday the FDA approved Brisdelle for moderate to severe hot flashes.  Brisdelle is low dose paroxetine or Paxil.
The committee that studied it recommended against approving it … but the FDA thought it was a good idea.    This is marketed to women who are afraid of cancer due to hormone replacement therapy – I wonder if they bother to tell the patients that there is a risk of withdrawal syndrome when they no longer have hot flashes.
I think this is a really BAD idea.  I predict that over some time we will see more visitors to our site looking for help getting off of Brisdelle … very sad.    Karma

20 )  deleted


22) http://www.medscape.com/viewarticle/711910
Pharmacotherapy  –  Use of Antidepressants for Management of Hot Flashes
Dana G. Carroll, Pharm.D., Kristi W. Kelley, Pharm.D.
Disclosures  Pharmacotherapy. 2009;29(11):1357-1374.

23) http://www.aafp.org/afp/2006/0201/p457.html
Nonhormonal Therapies for Hot Flashes in Menopause
DANA G. CARROLL, PHARM.D., B.C.P.S., University of Oklahoma–Tulsa College of Medicine, Tulsa, Oklahoma
Am Fam Physician. 2006 Feb 1;73(3):457-464.

24) http://www.webmd.com/menopause/antidepressants-for-hot-flashes
Antidepressants for Hot Flashes
Examples –
Generic Name     Brand Name
fluoxetine     Prozac
paroxetine     Paxil
venlafaxine     Effexor
escitalopram     Lexapro


25) http://www.ncbi.nlm.nih.gov/pubmed/16192581
J Clin Oncol. 2005 Oct 1;23(28):6919-30.
Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial.   Stearns V, Slack R, Greep N, Henry-Tilman R, Osborne M, Bunnell C, Ullmer L, Gallagher A, Cullen J, Gehan E, Hayes DF, Isaacs C. Source Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC, USA.

In an open-label trial we have previously demonstrated that paroxetine reduces hot flashes. We initiated a stratified, randomized, double-blind, cross-over, placebo-controlled trial to investigate the efficacy of paroxetine 10 mg and 20 mg compared to placebo in reducing hot flash frequency and composite score. A secondary objective was to evaluate quality of life (QOL) parameters.
PATIENTS AND METHODS:Women who suffered at least two hot flashes a day for 1 month or longer were eligible. Women were randomly assigned to 4 weeks of paroxetine 10 mg or 20 mg followed by placebo for 4 weeks, or placebo for 4 weeks followed by paroxetine 10 mg or 20 mg for 4 weeks. Participants completed baseline daily hot flash diaries for one week prior to the start of the study and throughout the study, and QOL questionnaires at baseline, week 5 and week 9.
RESULTS:279 women were screened, and 151 were randomly assigned.

Paroxetine 10 mg reduced hot flash frequency and composite score by 40.6% and 45.6%, respectively, compared to 13.7% and 13.7% for placebo (P = .0006 and P = .0008, respectively).

Paroxetine 20 mg reduced hot flash frequency and composite score by 51.7% and 56.1%, respectively, compared with 26.6% and 28.8% for placebo (P = .002 and P = .004, respectively). Efficacy was similar between the two doses, but women were less likely to discontinue low-dose paroxetine. Paroxetine 10 mg was associated with a significant improvement in sleep compared with placebo (P = .01).
CONCLUSION:Paroxetine is an effective treatment for hot flashes in women with or without a prior breast cancer.

26) http://www.ncbi.nlm.nih.gov/pubmed/10690382
Ann Oncol. 2000 Jan;11(1):17-22.
A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors.  Stearns V, Isaacs C, Rowland J, Crawford J, Ellis MJ, Kramer R, Lawrence W, Hanfelt JJ, Hayes DF.   Source  Breast Cancer Program, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA.
BACKGROUND:  Many breast cancer survivors suffer debilitating hot flashes. Estrogen, the drug of choice in perimenopausal women, is generally not recommenced to breast cancer survivors. Nonhormonal treatments are mostly disappointing. Anecdotal reports in our institution suggested that the selective serotonin-reuptake inhibitor, paroxetine hydrochloride, might be efficacious in alleviating hot flashes.
PATIENTS AND METHODS:  Thirty women with prior breast cancer who were suffering at least two hot flashes a day entered a single institution pilot trial to evaluate paroxetine’s efficacy in reducing the frequency and severity of hot flashes. After completing daily diaries for one week on no therapy, the women received open-label paroxetine, 10 mg daily for one week, followed by four weeks of paroxetine, 20 mg daily. The women completed hot-flash daily diaries throughout the study period, and a health-related symptom-assessment questionnaire and a quality-of-life rating scale in the first and sixth week of the study.
RESULTS:  Twenty-seven women completed the six-week study period.

The mean reduction of hot flash frequency was 67% (95% confidence interval (95% CI): 56%-79%). The mean reduction in hot flash severity score was 75% (95% CI: 66%-85%). There was a statistically significant improvement in depression, sleep, anxiety, and quality of life scores. Furthermore, 25 (83%) of the study participants chose to continue paroxetine therapy at the end of study. The most common adverse effect was somnolence, resulting in drug discontinuation in two women, and dose reduction in two women. One woman discontinued drug due to anxiety.
CONCLUSIONS: Paroxetine hydrochloride is a promising new treatment for hot flashes in breast cancer survivors, and warrants further evaluation in a double-blind randomized placebo-controlled trial.

27) http://www.ncbi.nlm.nih.gov/pubmed/12783913
JAMA. 2003 Jun 4;289(21):2827-34.
Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.  Stearns V, Beebe KL, Iyengar M, Dube E.
Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, USA.   Standard therapy for hot flashes has been hormone replacement with estradiol or progestational agents, but recent data suggest that antidepressants inhibiting serotonin reuptake may also be effective.  To evaluate a selective serotonin reuptake inhibitor (paroxetine controlled release [CR]) in treating the vasomotor symptoms displayed by a general cross-section of menopausal women.  Randomized, double-blind, placebo-controlled, parallel group study conducted across 17 US sites, including urban, suburban, and rural clinics.  A total of 165 menopausal women aged 18 years or older experiencing at least 2 to 3 daily hot flashes and must have discontinued any hormone replacement therapy for at least 6 weeks. Women were excluded if they had any signs of active cancer or were undergoing chemotherapy or radiation therapy.
After a 1-week placebo run-in phase, study participants were randomized to receive placebo or receive 12.5 mg/d or 25.0 mg/d of paroxetine CR (in a 1:1:1 ratio) for 6 weeks.
Fifty-six participants were randomly assigned to receive placebo and 51 to receive 12.5 mg/d and 58 to receive 25.0 mg/d of paroxetine CR. The mean reductions in the hot flash frequency composite score from baseline to week 6 were statistically significantly greater for those receiving paroxetine CR than for those receiving placebo.

By week 6, the mean daily hot flash frequency went from 7.1 to 3.8 (mean reduction, 3.3) for those in the 12.5-mg/d and from 6.4 to 3.2 (mean reduction, 3.2) for those in the 25-mg/d paroxetine CR groups and from 6.6 to 4.8 (mean reduction, 1.8) for those in the placebo group. Mean placebo-adjusted reduction in hot flash composite scores were -4.7 (95% confidence interval, – 8.1 to -1.3; P =.007) comparing 12.5-mg/d paroxetine CR with placebo; and -3.6 (95% confidence interval, -6.8 to -0.4; P =.03) comparing 25.0-mg/d paroxetine CR with placebo. This corresponded to median reductions of 62.2% for those in the 12.5-mg/d and 64.6% for those in the 25.0-mg/d paroxetine CR groups compared with 37.8% for those in the placebo group.
CONCLUSION:Paroxetine CR may be an effective and acceptable alternative to hormone replacement and other therapies in treating menopausal hot flash symptoms.

28) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2698018/
J Clin Oncol. 2009 June 10; 27(17): 2831–2837.
Newer Antidepressants and Gabapentin for Hot Flashes: An Individual Patient Pooled Analysis .   Charles L. Loprinzi, Jeff Sloan, Vered Stearns, Rebecca Slack, Malini Iyengar, Brent Diekmann, Gretchen Kimmick, James Lovato, Paul Gordon, Kishan Pandya, Thomas Guttuso, Jr, Debra Barton, and Paul Novotny

Homeopathic Medicine for Hot Flashes

29) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585763/
Drugs R D. 2012 September; 12(3): 107–119.
Published online 2012 December 18. doi:  10.2165/11640240-000000000-00000
PMCID: PMC3585763

Efficacy of a Non-Hormonal Treatment, BRN-01, on Menopausal Hot Flashes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Jean-Claude Colau, Stéphane Vincent, PharmD,corresponding author Philippe Marijnen, and François-André Allaert

Treatment was either BRN-01 tablets, a registered homeopathic medicine containing Actaea racemosa (4 centesimal dilutions [4CH]), Arnica montana (4CH), Glonoinum (4CH), Lachesis mutus (5CH), and Sanguinaria canadensis (4CH), or identical placebo tablets, prepared by Laboratoires Boiron according to European Pharmacopoeia standards. Oral treatment (2 to 4 tablets per day) was started on day 3 after study enrollment and was continued for 12 weeks.
BRN-01 seemed to have a significant effect on the HFS, compared with placebo. According to the results of this clinical trial, BRN-01 may be considered a new therapeutic option with a safe profile for hot flashes in menopausal women who do not want or are not able to take hormone replacement therapy or other recognized treatments for this indication.


Financial Disclosures  Charles L. Loprinzi, MD,

Professor of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota .  Interviewee Disclosure: Charles L. Loprinzi, MD, has disclosed that he has served as a consultant for Concert Pharmaceuticals.  Grant/Research/Clinical Trial Support: Pfizer  Dr. Loprinzi had disclosed that he has received research funding from the North Central Cancer Treatment Group.
2011 ASCO Annual Meeting ‐ Committee Disclosures
Reserach funding from:  Abbott Laboratories Amgen Bristol-Myers Squibb Eisai Novartis Ortho Biotech Roche sanofi-aventis

30) http://www.clinicalneurologynews.com/index.php?id=9985&type=98&tx_ttnews[tt_news]=134747&cHash=da03e20e36
Dr. Loprinzi disclosed receiving research funding from Abbott, Amgen, Bristol-Myers Squibb, Eisai, Novartis, Ortho Biotech, Pfizer, Roche, and Sanofi.

Vered Stearns Financial Disclosures

31) http://www.zoominfo.com/p/Vered-Stearns/1450702927
Financial Disclosure: Dr. Stearns has received investigator-initiated grants from
Abraxis, Merck, Novartis, and Pfizer, and has received honoraria from AstraZeneca.


32) http://www.washingtonpost.com/wp-dyn/content/article/2007/01/05/AR2007010500180.html
Unequal Treatment Reviewed by Alondra Nelson Sunday, January 7, 2007
MEDICAL APARTHEID-  The Dark History of Medical Experimentation on Black Americans From Colonial Times to the Present  By Harriet A. Washington

33) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844275/
Med Hist. 2010 April; 54(2): 171–194.  “Divine Stramonium”: The Rise and Fall of Smoking for Asthma  MARK JACKSON*

34) Instinct Based Medicine: How to Survive Your Illness and Your Doctor By Leonard Coldwell


Briefly, we will look at the medical iatrogenesis of women in particular. Dr. Martin Charcot (1825-1893) was world-renowned, the most celebrated doctor of his time. He practiced in the Paris hospital La Salpetriere. He became an expert in hysteria diagnosing an average of 10 hysterical women each day, transforming them into … “iatrogenic monsters,” turning simple ‘neurosis’ into hysteria.96 The number of women diagnosed with hysteria and hospitalized rose from one percent in 1841 to 17 percent in 1883.

Hysteria is derived from the Latin “hystera,” meaning uterus.

Dr. Adriane Fugh-Berman stated very clearly in her paper that there is a tradition in U.S. medicine of excessive medical and surgical interventions on women. Only 100 years ago male doctors decided that female psychological imbalance originated in the uterus. When surgery to remove the uterus was perfected it became the “cure” for mental instability, effecting a physical and psychological castration.

Dr. Fugh-Berman noted that U.S. doctors eventually disabused themselves of that notion but have continued to treat women very differently than they treat men.97 She cites the following:

Thousands of prophylactic mastectomies are performed annually.
One-third of U.S. women have had a hysterectomy before menopause.
Women are prescribed drugs more frequently than are men.
Women are given potent drugs for disease prevention, which results in disease substitution due to side effects.
Fetal monitoring is unsupported by studies and not recommended by the CDC.98 It confines women to a hospital bed and may result in higher incidence of cesarean section.99
Normal processes such as menopause and childbirth have been heavily medicalized.
Synthetic hormone replacement therapy (HRT) does not prevent heart disease or dementia. It does increase the risk of breast cancer, heart disease, stroke, and gall bladder attack.100

We would add that as many as one-third of postmenopausal women use HRT.101,102 These numbers are important in light of the much-publicized Women’s Health Initiative Study, which was forced to stop before its completion because of a higher death rate in the synthetic estrogen-progestin (HRT) group.103

Cesarean Section

In 1983, 809,000 cesarean sections (21 percent of live births) were performed, making it the most common obstetric and gynecologic (OB/GYN) surgical procedure.

The second most common OB/GYN operation was hysterectomy (673,000), and diagnostic dilation and curettage of the uterus (632,000) was third. In 1983, OB/GYN operations represented 23 percent of all surgery completed in this country.104

In 2001, Cesarean section is still the most common OB/GYN surgical procedure. Approximately 4 million births occur annually, with a 24 percent C-Section rate, i.e., 960,000 operations. In the Netherlands only eight percent of babies are delivered by Cesarean section. Assuming human babies are similar in the United States and in the Netherlands, we are performing 640,000 unnecessary C-Sections in the United States with its three to four times higher mortality and 20 times greater morbidity than vaginal delivery.105

The cesarean section rate was only 4.5 percent in the United States in 1965. By 1986 it had climbed to 24.1 percent. The author states that obviously an “uncontrolled pandemic of medically unnecessary cesarean births is occurring.”106 VanHam reported a cesarean section postpartum hemorrhage rate of seven percent, a hematoma formation rate of 3.5 percent, a urinary tract infection rate of three percent, and a combined postoperative morbidity rate of 35.7 percent in a high-risk population undergoing cesarean section.107

35) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3238324/
Yale J Biol Med. 2011 December; 84(4): 471–478.
Medical Reversal: Why We Must Raise the Bar Before Adopting New Technologies
Vinay Prasad, MDa and Adam Cifu, MDb,*

36) http://jama.jamanetwork.com/article.aspx?articleid=1104821
Reversals of Established Medical Practices Evidence to Abandon Ship
Vinay Prasad, MD; Adam Cifu, MD; John P. A. Ioannidis, MD, DSc
JAMA. 2012;307(1):37-38. doi:10.1001/jama.2011.1960.

Ideally, good medical practices are replaced by better ones, based on robust comparative trials in which new interventions outperform older ones and establish new standards of care. Often, however, established standards must be abandoned not because a better replacement has been identified but simply because what was thought to be beneficial was not. In these cases, it becomes apparent that clinicians, encouraged by professional societies and guidelines, have been using medications, procedures, or preventive measures in vain. For example, percutaneous coronary intervention performed for stable coronary artery disease and hormone therapy prescribed for postmenopausal women cost billions of dollars and supported the existence of entire specialties for many years. Stable coronary artery disease accounted for 85% of all stenting in the United States at the time of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.1 Large, well-designed randomized trials that tested whether these practices improved major patient outcomes revealed that patients were not being helped. Defenders of these therapies and interventions wrote rebuttals and editorials and fought for their specialties, but the reality was that the best that could be done was to abandon ship.

37) http://www.ncbi.nlm.nih.gov/pubmed/16060722/
PLoS Med. 2005 Aug;2(8):e124. Epub 2005 Aug 30.
Why most published research findings are false. Ioannidis JP. Source Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.

There is increasing concern that most current published research findings are false. The probability that a research claim is true may depend on study power and bias, the number of other studies on the same question, and, importantly, the ratio of true to no relationships among the relationships probed in each scientific field. In this framework, a research finding is less likely to be true when the studies conducted in a field are smaller; when effect sizes are smaller; when there is a greater number and lesser preselection of tested relationships; where there is greater flexibility in designs, definitions, outcomes, and analytical modes; when there is greater financial and other interest and prejudice; and when more teams are involved in a scientific field in chase of statistical significance. Simulations show that for most study designs and settings, it is more likely for a research claim to be false than true. Moreover, for many current scientific fields, claimed research findings may often be simply accurate measures of the prevailing bias. In this essay, I discuss the implications of these problems for the conduct and interpretation of research.

38) http://www.ncbi.nlm.nih.gov/pubmed/12153921/
BMJ. 2002 Aug 3;325(7358):249.
Association between competing interests and authors’ conclusions: epidemiological study of randomised clinical trials published in the BMJ.  Kjaergard LL, Als-Nielsen B.
Cochrane Hepatobiliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Department 7102, H:S Rigshospitalet, DK-2100 Copenhagen, Denmark.

To assess the association between competing interests and authors’ conclusions in randomised clinical trials.
DESIGN:Epidemiological study of randomised clinical trials published in the BMJ from January 1997 to June 2001. Financial competing interests were defined as funding by for profit organisations and other competing interests as personal, academic, or political. Studies: 159 trials from 12 medical specialties.
MAIN OUTCOME MEASURES:Authors’ conclusions defined as interpretation of extent to which overall results favoured experimental intervention. Conclusions appraised on 6 point scale; higher scores favour experimental intervention.
RESULTS:Authors’ conclusions were significantly more positive towards the experimental intervention in trials funded by for profit organisations alone compared with trials without competing interests (mean difference 0.48 (SE 0.13), P=0.014), trials funded by both for profit and non-profit organisations (0.30 (SE 0.10), P=0.003), and trials with other competing interests (0.45 (SE 0.13), P=0.006). Other competing interests and funding from both for profit and non-profit organisations were not significantly associated with authors’ conclusions. The association between financial competing interests and authors’ conclusions was not explained by methodological quality, statistical power, type of experimental intervention (pharmacological or non-pharmacological), type of control intervention (for example, placebo or active drug), or medical specialty.
CONCLUSIONS: Authors’ conclusions in randomised clinical trials significantly favoured experimental interventions if financial competing interests were declared. Other competing interests were not significantly associated with authors’ conclusions.


42) (3) http://www.nejm.org/doi/pdf/10.1056/NEJM197104222841604  Adenocarcinoma of the Vagina — Association of Maternal Stilbestrol Therapy with Tumor Appearance in Young Women.  Arthur L. Herbst, M.D., Howard Ulfelder, M.D., and David C. Poskanzer, M.D. N Engl J Med 1971; 284:878-881April 22, 1971

43) (4) http://www.jstor.org/pss/2683841  Epidemiologic Evidence for Adverse Effects of DES Exposure during Pregnancy Theodore Colton and E. Robert Greenberg The American Statistician Vol. 36, No. 3, Part 2: Proceedings of the Sixth Symposium on Statistics and the Environment (Aug., 1982), pp. 268-272

44) (5) http://ajph.aphapublications.org/cgi/reprint/70/3/264.pdf  The Epidemic of Endometrial Cancer:A Commentary Hershel Jick et al.Am J Public Health 70:264-267, 1980.

45) (6) http://www.nejm.org/doi/full/10.1056/NEJM197512042932303 Increased Risk of Endometrial Carcinoma among Users of Conjugated Estrogens.  Harry K. Ziel, M.D., and William D. Finkle, Ph.D. N Engl J Med 1975; 293:1167-1170 December 4, 1975

46) (7) http://www.ncbi.nlm.nih.gov/pubmed/213722  N Engl J Med. 1979 Jan 4;300(1):9-13. Endometrial cancer and estrogen use. Report of a large case-control study. Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R.

47) (8)  http://www.ncbi.nlm.nih.gov/pubmed/3358913
The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk.Key TJ, Pike MC.
Br J Cancer. 1988 Feb;57(2):205-12.

48) (9) http://jama.ama-assn.org/content/283/4/485.abstract   Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk. Catherine Schairer, PhD et al.  JAMA. 2000;283(4):485-491.

49) (10) http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0215(19960729)67:3%3C327::AID-IJC4%3E3.0.CO;2-T/pdf 
see also http://www.ncbi.nlm.nih.gov/pubmed/8707404
Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy—long-term follow-up of a Swedish cohort.  Ingemar Persson et al. International Journal of Cancer Volume 67, Issue 3, pages 327–332, 29 July 1996

50) (11) http://www.ncbi.nlm.nih.gov/pubmed/12927427    Lancet. 2003 Aug 9;362(9382):419-27. Breast cancer and hormone-replacement therapy in the Million Women Study. Beral V; Million Women Study Collaborators.

51) 12) http://jama.ama-assn.org/cgi/content/abstract/288/3/321
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women
Principal Results From the Women’s Health Initiative Randomized Controlled Trial
Writing Group for the Women’s Health Initiative Investigators JAMA. 2002;288:321-333.


52) http://jama.ama-assn.org/cgi/content/abstract/303/1/47
Fournier JC, DeRubeis RJ, Hollon SD; et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47-53


PAxil Withdrawal Symptoms

[1] International Journal of Neuorpsychopharmacology, Fava GA, et al., “Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia” (16 January 2007) , http://www.ncbi.nlm.nih.gov/pubmed/17224089?dopt=AbstractPlus

[2] USA Today, AP, “Judge: Paxil ads can’t say it isn’t habit-forming,” (20 August 2002), http://usatoday30.usatoday.com/news/health/2002-08-20-paxil-ads_x.htm

BMJ., Tonks A., “Withdrawal from paroxetine can be severe, warns FDA” (2 February 2002), http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1122195/

[3] Ann Med Interne (Paris), Belloef L. at al., “Paroxetine withdrawal syndrome” (April 2000), http://www.ncbi.nlm.nih.gov/pubmed/10855379

[4] Drug Saf., Haddad PM., “Antidepressant discontinuation syndromes” (2001), http://www.ncbi.nlm.nih.gov/pubmed/11347722

Stiskal, J., et al. “Neonatal paroxetine withdrawal syndrome.” Archives of disease in childhood. Fetal and neonatal edition 84.2 (2001): F134.Neonatal paroxetine withdrawal syndrome Stiskal Archives disease childhood Fetal and neonatal edition 2001

http://www.jpma.org.pk/full_article_text.php?article_id=1054; Journal of Pakistan Medical Association, Ahmed M., “Neonatal convulsions secondary to paroxetine withdrawal” (March 2007),

http://www.ncbi.nlm.nih.gov/pubmed/14689334 Z Geburtshilfe Neonatol., Herbst F. and Gortner L., “Paroxetine withdrawal syndrome as differential diagnosis of acute neonatal encephalopathy?” (November- December 2003),

Paxil not effective in Depression

NEJM, Turner EH et al.,”Selective publication of antidepressant trials and its influence on apparent efficacy,” (17 January 2008), http://www.ncbi.nlm.nih.gov/pubmed/18199864

A 2008 review of clinical trials reported to the FDA found that studies used to get FDA approval of SSRI anti-depressants were not published accurately, that unfavorable results were not published and in some cases published in a way that made them falsely appear to be favorable.[2]

New York Times, “MEDICINE’S DATA GAP: Selective Disclosure; Two Studies, Two Results, And a Debate Over a Drug” (3 June 2004),http://www.nytimes.com/2004/06/03/business/medicine-s-data-gap-selective-disclosure-two-studies-two-results-debate-over.html?pagewanted=all&src=pm;

Cunningham, et al. v SmithKline Beecham Corp. et al., United States District Court for the Eastern District of Pennsylvania, Case No. CA NO06-3022-TJS, Deposition of Sally K. Laden, 15 March 2007, pp. 80-81, 97, 113, 169-71, http://pogoarchives.org/m/ph/sally-laden-sti-deposition-20070315.pdf

healthyskepticism.org, Jureidini J., “Paxil Study 329: Paroxetine vs Imipramine vs Placebo in Adolescents” (January 2010), http://www.healthyskepticism.org/global/news/int/hsin2010-01

Adverse side effects
The FDA reports side effects of Paxil include the risk of suicide and suicidal thoughts or actions, serotonin syndrome or neuroleptic malignant syndrome-like reactions, severe allergic reactions (trouble breathing, swelling of face, tongue, eyes or mouth, rash), abnormal bleeding, seizures or convulsions, manic episodes, changes in appetite or weight, low salt levels in blood.[2]

Common paxil side effects include nausea, sleepiness, weakness, dizziness, feeling anxious or trouble sleeping, asexual problems, sweating, shaking, not feeling hungry, dry mount, constipation, infection and yawning.[3]

[1] Food and Drug Administration, “Class Suicidality Labeling Language for Antidepressants” (2005), http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20031s045,20936s020lbl.pdf

[2] Food and Drug Administration, Paxil Medication Guide (July 2011), http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088676.pdf

Withdrawal Syndrome

[1] International Journal of Neuorpsychopharmacology, Fava GA, et al., “Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia” (16 January 2007) , http://www.ncbi.nlm.nih.gov/pubmed/17224089?dopt=AbstractPlus

[2] USA Today, AP, “Judge: Paxil ads can’t say it isn’t habit-forming,” (20 August 2002), http://usatoday30.usatoday.com/news/health/2002-08-20-paxil-ads_x.htm

BMJ., Tonks A., “Withdrawal from paroxetine can be severe, warns FDA” (2 February 2002), http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1122195/

In a class-action suit against Paxil’s manufacturer, a federal judge ruled that GlaxoSmithKline (GSK) had falsely advertised that Paxil wasn’t habit forming and couldn’t make that claim in advertising. Thirty-five patients in this action had reported that they had experienced withdrawal symptoms including nausea, fever and “electric zaps” in their bodies.[2]

[3] Ann Med Interne (Paris), Belloef L. at al., “Paroxetine withdrawal syndrome” (April 2000), http://www.ncbi.nlm.nih.gov/pubmed/10855379

[4] Drug Saf., Haddad PM., “Antidepressant discontinuation syndromes” (2001), http://www.ncbi.nlm.nih.gov/pubmed/11347722

[5] Arch Dis Child Fetal Neonatal Ed., Stiskal N. et al., “Neonatal paroxetine withdrawal syndrome” (March 2001), http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1721229/, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1721229/pdf/v084p0F134.pdf; Journal of Pakistan Medical Association, Ahmed M., “Neonatal convulsions secondary to paroxetine withdrawal” (March 2007), http://www.jpma.org.pk/full_article_text.php?article_id=1054; Z Geburtshilfe Neonatol., Herbst F. and Gortner L., “Paroxetine withdrawal syndrome as differential diagnosis of acute neonatal encephalopathy?” (November- December 2003), http://www.ncbi.nlm.nih.gov/pubmed/14689334


Paxil – Antidepressant Drug with Dangerous Side Effects

Paxil Withdrawal Case Settled in California

Jeffrey Dach MD
7450 Griffin Road
Davie, Fl 33314

Click Here for: Dr Dach’s Online Store for Pure Encapsulations Supplements Click Here for: Dr Dach’s Online Store for Nature’s Sunshine Supplements

Web Site and Discussion Board Links:


Disclaimer click here: http://www.drdach.com/wst_page20.html

The reader is advised to discuss the comments on these pages with his/her personal physicians and to only act upon the advice of his/her personal physician. Also note that concerning an answer which appears as an electronically posted question, I am NOT creating a physician — patient relationship. Although identities will remain confidential as much as possible, as I can not control the media, I can not take responsibility for any breaches of confidentiality that may occur.

Link to this article  http://wp.me/p3gFbV-vs

Copyright (c) 2010-2013 Jeffrey Dach MD All Rights Reserved. This article may be reproduced on the internet without permission, provided there is a link to this page and proper credit is given.

FAIR USE NOTICE: This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of issues of significance. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.Demonstration-of-Hysteria-by-Charcot

Last updated on by Jeffrey Dach MD

FDA Approval for Paxil for Hot Flashes A Cruel Joke ?
Article Name
FDA Approval for Paxil for Hot Flashes A Cruel Joke ?
Prescibing Paxil for Menopausal Hot Flashes is medical abuse and should be halted.
Jeffrey Dach MD
publisher logo

One thought on “FDA Approval for Paxil for Hot Flashes A Cruel Joke ?

  1. This article explores SSRI antidepressants in great detail. One of the important things is the use of Paroxetine for anxiety and panic disorder. Hot flashes are also one of the uncomfortable anxiety symptoms. There is need of promoting Cognitive Behavior therapy and Exposure therapy for anxiety and depression disorders instead of these drugs since they do not demonstrate efficacy higher than placebos. I write on anxiety at http://panictermination.com/

Leave a Reply